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Abstract Adults diagnosed with Glioblastoma multi-
forme (GBM) are frequently faced with a 7% chance of
surviving 2 years compared with pediatric patients with
GBM who have a 26% survival rate. Our recent screen of
possible glioma-associated antigen precursor protein
(TAPP) proﬁles displayed from different types of pediatric
brain tumors showed that pediatric patients contained a
subset of the tumor antigens displayed by adult GBM
patients. Adult GBM possess at least 27 tumor antigens that
can potentially stimulate T cell immune responses, sug-
gesting that these tumors are quite antigenic. In contrast,
pediatric brain tumors only expressed nine tumor antigens
with mRNA levels that were equivalent to those displayed
by adult GBM. These tumor-associated antigens could be
used as possible targets of therapeutic immunization for
pediatric brain cancer patients. Children have developing
immune systems that peak at puberty. An immune response
mounted by these pediatric patients might account for their
extended life spans, even though the pediatric brain tumors
express far fewer total tumor-associated antigens. Here we
present a hypothesis that pediatric brain tumor patients
might be the best patients to show that immunotherapy can
be used to successfully treat established cancers. We
speculate that immunotherapy should include a panel of
tumor antigens that might prevent the out-growth of more
malignant tumor cells and thereby prevent the brain tumor
relapse. Thus, pediatric brain tumor patients might provide
an opportunity to prove the concept of immunoprevention.
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Background
Glioblastoma multiforme (GBM) from adult patients look
morphologically identical to those GBM derived from
pediatric patients. The cell growth patterns, vascular supply
and pathology including the central pallisading necrosis are
indistinguishable from each other. Adult GBM patients
(ages [55) have a 2 year survival less than 7% (without
temozolomide), compared with 26% survival of pediatric
GBM (without temozolomide) [1]. Since there is a differ-
ence in survival between the two GBM patient populations,
the question remains whether these GBMs are two separate
diseases arising from two different genetic defects that
converge into the same pathology or just one disease that
diverges due to selective pressures within the host. Fig-
ure 1 compares the differences in life expectancies among
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[panel b] and GBM [panel c] patients by age; i.e., pediatric
(0–19 years) and adult (45–74 years) patients. The 10 year
survivals of pediatric patients with other subtypes of
pediatric brain tumors are much longer compared with
GBM. For low grade gliomas like ﬁbrillary astrocytomas it
is 81%, while survival for pilocytic astrocytoma patients is
93%. Overall, the survival of pediatric patients with these
different types of brain cancers is better than those found in
the corresponding adult patients as reported by Central
Brain Tumor Registry (CBTR). Therefore some differences
(either genetic and/or non-genetic) are responsible for these
different outcomes. Further investigations as discussed
here may allow advances to be applicable to the treatment
of adults and children diagnosed with brain cancers.
Our recent Journal of Neuro-Oncology paper [2]
examined the expression of 31 possible ‘‘glioma-associ-
ated’’ antigen precursor proteins (TAPP) by quantitative
real time PCR (qRT-PCR) techniques from 37 human brain
tumor patients. Our study included: 11 adult GBM (3
recurrent), 5 pediatric GBM (1 recurrent), 4 primary low-
grade ﬁbrillary gliomas and 10 primary juvenile pilocytic
astrocytomas. These ‘‘glioma-associated’’ antigens we used
to generate TAPP proﬁles were selected based on prior
studies by others, who showed human cytotoxic T lym-
phocyte (CTL) responses were induced by these antigenic
peptides against a wide range of cancers from adults. In
addition, these proteins are expressed or over-expressed by
glioma cells. We initially speculated that the TAPP proﬁles
of both the adult and pediatric GBM would be identical,
since they are histopathologically indistinguishable from
each other. We also postulated that the other tumor sub-
types would have different TAPP proﬁles from pediatric
patients, because they were morphologically different
cancers. Unexpectedly, we saw that there were four
different global TAPP proﬁles of tumor antigens among the
adult GBM and the pediatric brain tumors.
In group 1, the adult GBM and the pediatric tumors
expressed the same amount of mRNA for 9 antigens. In
group 2, the adult GBM expressed more mRNA for 9
antigens compared with the pediatric brain tumors. For
group 3, only the adult GBM expressed mRNAs for 9
different antigens, while in group 4, there was no consistent
expression of mRNA for 4 of the tumor antigens. The
antigen proﬁle of the adult GBM was unexpectedly dif-
ferent from the pediatric GBM. The pediatric GBM TAPP
expression proﬁle was a smaller subset of the antigens
displayed by the adult GBM. Additionally, most of the
other pediatric brain tumors (low grade ﬁbrillary astrocy-
tomas, pilocytic astrocytomas and ependymomas) had
TAPP proﬁles that were more similar to each other and to
pediatric GBM than they were different from each other.
Table 1 (reproduced with permission) lists the TAPP
antigenic proﬁles of the various tumors from our studies.
One empirical observation was that the adult GBM
expressed many more tumor antigens (total of 27 out of 31
antigens), compared with the pediatric brain tumors which
all presented fewer tumor antigens (ranges of 8–17 anti-
gens/tumor type). One limitation to our study was that we
only examined mRNA and not the protein and/or the
peptides needed for MHC binding. In our prior study using
GBM cell lines where we examined 16 tumor antigens [3],
the amount of the mRNA levels correlated very well with
the protein as detected by immunostaining and intracellular
ﬂow cytometry; i.e.; high mRNA levels showed high pro-
tein expression and cells that had little or no mRNA had
little or no protein expression, respectively. So if our study
with freshly isolated surgical specimens can be extrapo-
lated to the protein/peptide level, we conclude that adult
GBM would actually be ‘‘more antigenic’’ to T cells than
pilocytic astrocytoma
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Fig. 1 Differences in survival between pediatric patients and adult
patients diagnosed with the same brain cancers (pilocytic astrocyto-
mas [panel a], protoplasmic & ﬁbrillary astrocytomas [panel b] and
glioblastoma multiforme [panel c]). Data taken from SEER (1973–
2004) is plotted for survival after 1, 2, 3, 4, 5 and 10 years after initial
diagnosis. The pediatric patients included those from 0 to 19 years,
while the adults were 45–74 years of age. The number of patients for
each group is shown in the legend boxes. By ANCOVA analysis the
pediatric pilocytic and ﬁbrillary astrocytoma patient are signiﬁcantly
different, P = 0.002 and P = 0.001, respectively from the adults. For
the GBM patients, the P value is 0.373
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123the corresponding pediatric GBM. This conclusion appears
paradoxical given the survival data shown in Fig. 1c. These
results raises the simple question: why doesn’t the
increased antigenicity of adult GBM lead to increased
immunogenicity, correlated perhaps with increased
survival?
Another caveat that must be noted is that the tumor-
associated antigens we have examined are those deﬁned
largely from adults with GBM, which could potentially
skew our proposed analysis. If pediatric GBM come from a
different set of genetic defects [4], then pediatric GBM
may have pediatric GBM-restricted TAPP, that are not seen
within the adult GBM. Hence pediatric brain cancer
researchers should be cognizant of this possibility. But this
offers possible fertile grounds to ﬁnd new pediatric brain
tumor-speciﬁc antigens.
Adult GBM have more defensive mechanisms
As described above, one TAPP expression proﬁle of 9
antigens was either expressed more in adult GBM compared
with pediatric GBM (group 2) or exclusively expressed in
adult GBM compared with pediatric GBM (group 3). We
will focus on 3 of these tumor antigens: Multi-drug resis-
tance protein-3 (MRP-3), human Telomerase reverse
transcriptase (hTert), and Survivin (Fig. 2). These 3 tumor
antigens may provide some insight into why pediatric GBM
may be easier to treat and why the pediatric GBM patients
survive longer than adult GBM patients. Expression of these
3 genes correlates with a poorer prognosis in many different
cancer types [5–8], suggesting these genes participate in
tumor progression. Studies have shown that CTLs are
capable of killing cancer cells expressing these 3 epitopes
[9–12].HencetheseadultGBMshouldstillbesusceptibleto
this T cell-mediated cytotoxicity.
MRP-3 is a reverse drug transporter that expels che-
motherapeutic drugs out of the tumor cells, making these
cells resistant to the actions of various cytotoxic com-
pounds. All 5 of the pediatric GBM samples displayed
lowered amounts of mRNA for this gene, compared with
the adult GBM. The one sample that had the highest MRP-
3 mRNA came from a primary GBM patient. Overall, this
difference in MRP-3 expression may help explain why
most pediatric GBM are probably more susceptible to
chemotherapy compared with adult GBM.
Table 1 Potential targeted antigens for immunotherapy of human brain cancers
Tumor type Antigens
Adult GBM Aim-2, Art-1*, Art-4, B-cyclin, EphA2*, Ezh2, Fosl1*, Galt-3, GnT-V*, Her2/Neu, HNRPL*,
IL13Ra2*, Mage-1, MRP-3*, PTH-rP, Sart-1*, Sart-2, Sart-3, Sox 11* Survivin, hTert, Trp-1,
Trp-2* Tyrosinase, Ube2V* Whsc2, YKL-40*
Pediatric GBM Art-1* EphA2*, Fosl1*, HNRPL*, MRP-3, Sox 11*, Trp-2*, Ube2V*, YKL-40*
Low grade ﬁbrillary astrocytomas Art-1*, B-cyclin, EphA2*, Ezh2, Fosl1*, GnT-V*, Her2/Neu, HNRPL*, IL13Ra2*,
MRP-3, Sart-1*, Sart-3, Sox 11*, Trp-2*, Ube2V*, Whsc2, YKL-40*
Juvenile pilocytic astrocytomas Art-1*, EphA2*, Ezh2, Fosl1*, HNRPL*, MRP-3*, Sart-2, Sox 11*, Ube2V*, Whsc2, YKL-40*
Ependymomas Ezh2, Fosl1*, Her2/Neu, HNRPL*, Sox 11*, Trp-2*, Ube2V*, YKL-40*
Asterisks indicate that the amount of mRNA was statistically equivalent
MRP-3
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Fig. 2 Differences between adult-derived and pediatric-derived for 3
TAPP genes. The amount of mRNA was quantitated by a DCt value
on left y-axis in comparison to the 18S RNA. The DCt value of 20 was
given an arbitrary value of 1 and the fold-difference is presented on
right y-axis. The expression of MRP-3, hTert and survivin are shown
within their respective boxes. Pediatric GBM patient 847 had the
highest expressing mRNA in the MRP-3 cohort, Pediatric GBM
patient 1292 displayed the most survivin mRNA and the second most
hTert mRNA. Pediatric GBM patient 1476 was the recurrent GBM
and had the most hTert mRNA. The legend box indicates the number
of tumors that were analyzed. By a student’s t test, all values between
the pediatric and adult GBM were statistically signiﬁcant (P\0.05)
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123hTert is the enzyme that stops the teleromeres from
shortening after each round of DNA replication. This poly-
merase therefore prevents the tumor cells from going into
senescence and/or dying of apoptosis after the chromosomal
teleromers reach their lower limits. Many low-grade brain
cancers can not be developed into established cell lines
because the tumor derived cells eventually become senes-
cent. This lack of hTert may help explain the inability to
propagate theselower grade glioma celllines. Twopediatric
GBMsamplesshowedlowlevelsofhTertexpression,which
we believe could be biologically relevant. The specimen
from the recurrent pediatric GBM had the highest hTert
mRNA expression within the pediatric GBM cohort. This
ﬁndingisimportantsincetumorselectionforrapidlyhTert?
growing clones could be occurring, which ultimately allows
the tumor cells to continue to proliferate preventing the
tumor cells from becoming senescent.
Survivin is an anti-apoptotic protein that functions on
several levels to make cells more resistant to apoptosis-
inducing pathways at either the nuclear or the cytoplasmic
levels. One pediatric patient with a primary GBM showed
expression of survivin mRNA that was equivalent to that
found in the adult GBM. Interestingly, this same patient
also showed some detectable level of hTert mRNA as well.
Three of the 5 pediatric GBM expressed low levels of
these protective molecules that could represent defense
mechanisms for the tumor cell, whereby the resistant cells
can be positively selected via drugs, radiation, or biological
therapies. The lack of a defense in pediatric GBM might be
the Achilles’ heel by which these brain tumors could be
successfully attacked by a properly activated immune
system.
Adult GBM, in addition to MRP-3, hTert and survivin,
have other defensive molecules in the following categories:
(1) anti-apoptotic genes like Bcl-2, Bcl-w, Mcl-1 [13],
inhibitor of apoptosis (IAPs) proteins [14]; (2) immuno-
suppressive agents like transforming growth factor-b [15],
interleukin-10 [16], prostaglandin via cyclo-oxygenase 2
[17]; (3) immune response; Treg involvement [18, 19],
decreased HLA expression, which prevent immune recog-
nition [20]; (4) other mechanisms reviewed in [21, 22].
These additional tumor defensive strategies by adult GBM
may account for the inability to generate/sustain lasting
immune responses in spite of increased antigenicity. The
role of these protective factors within pediatric brain tumors
is presently unknown and deserves future investigations.
Clinical success of treating pediatric brain tumor
patients comes at a price
Successful clinical interventions of pediatric patients by
chemo and radiation therapies do come at a price that is not
immediately obvious by the survival statistics shown in
Fig. 1. Pathological changes in treated brain tissues take
months to years to develop and include white and gray
matter abnormalities, microvascular occlusions, calciﬁca-
tions and demyelination [reviewed in 23, 24]. These
physiological changes translate into behavioral and devel-
opmental issues, such as loss of IQ [25]. Some studies
report that 40–100% of their patients have neurocognitive
problems [23], perceptual skill defects, learning disabilities
which ultimately results in academic failure. Long term
survivors later develop serious social/psychological prob-
lems that prevent them from becoming productive mem-
bers of society. These patients often can’t maintain steady
jobs, develop drug dependence, and have general psycho-
logical distress, along with failed marriages. These cogni-
tive and behavioral health issues could be due to the toxic
effects of drugs and radiation upon the developing neuronal
and supporting stromal cell networks. These sequela are
less visible in adults, because their overall survival is
shorter. Thus, there is a dire need for therapies that improve
the quality of life issue of pediatric patients and immuno-
therapy may be one avenue to accomplish this goal.
Current status of immunotherapy for brain tumors
There is some circumstantial evidence that the immune
system plays a role in the patient’s survival with brain
cancer. Atopic patients (13 out of 115 patients with ele-
vated IgE levels, P\0.0007) in the San Francisco area
had a lowered risk of developing glioma [26]. Additionally;
those glioma patients with elevated IgE levels survived
9 months longer [26]. This atopic relationship was con-
ﬁrmed in a meta-analysis compiled from eight independent
studies using 3,450 glioma patients [27]. Interleukin-4 (IL-
4), made by T helper type 2 cells, is commonly associated
with the production of IgE by B cells. IL-4 gene therapy in
rats also produced enhanced glioma survival [28, 29]. It
was assumed that this increased survival was due to the
actions of immunized T cells, but other explanations could
be possible. Recently it was shown that interleukin-4 and
granulocyte-macrophage colony stimulating factor acti-
vated human dendritic cells (DC) could directly kill several
human glioma cells in vitro [30]. Machulla et al. [31] and
Tang et al. [32] showed statistical associations of GBM
incidence with certain HLA phenotypes. Tang et al. [32]
studied 155 GBM patients and concluded those patients,
who possessed the HLA-B55 antigen died signiﬁcantly
quicker (relative risk: 2.27; P\0.01) than non-HLA-B55
patients. In contrast, those HLA-A32? GBM patients
survived signiﬁcantly longer (relative risk: 0.45; P\0.01).
The identiﬁcation of these various mechanisms of anti-
glioma activities need further investigation and may
162 J Neurooncol (2010) 97:159–169
123provide additional insight that could be fully exploited by
clinicians.
Cell-based immunotherapy has been viewed as a bright
hope to treat many types of cancers. The theoretical
advantage of these immune effectors is that they can
migrate throughout the body and actively seek out and
destroy the tumor cells. These effector lymphocytes should
remain present until the cancer is eliminated and then
memory T cells could be generated. Over the years, several
techniques have produced a few long-term successes [33–
41]. Effector lymphocytes like CTLs, lymphokine acti-
vated killer (LAK) cells, mitogen activated killer cells and
mixed lymphocyte reactive cells have been effective in
killing gliomas in vitro. Success has only occurred spo-
radically in a few GBM patients after being treated with
these activated lymphocytes. These sporadic successes
nevertheless have further spurred clinical research.
Dranoff et al.’s study [42] with murine melanomas was
instrumental in showing that more effective and durable
immune responses were generated by activating the host’s
dendritic cells, ﬁrst, rather than just stimulating effector T
cells. This study showed that immunization with B16
melanoma cells transduced with granulocyte-macrophage
colony stimulating factor (GM-CSF) and IL-4, but not with
interleukin-2 (IL-2) or tumor necrosis factor (TNF) trans-
duced cells, produced lasting immunity. They attributed
this response to the host’s dendritic cells functioning as
antigen presenting cells (APC), which stimulated the host’s
effector lymphocytes. Additionally, better memory T cells
are thought to be produced via this dendritic cell’s APC
function. Recent studies from Europe [43], UCLA [44] and
Cedar-Sinai [45] have shown that the mean time to pro-
gression for adult GBM patients increased in some
responder populations by vaccination with the patient’s
dendritic cells pulsed with autologous tumor homogenates.
One key ﬁnding that has been repeatedly reported is that
this immunotherapy is relatively safe with few serious side
effects. Most likely, this dendritic cell-based immunother-
apy will be used as an adjunct therapy after chemo- and
radiation therapies are administered, as opposed to a stand-
alone therapy. There have been some studies that show that
immunotherapy can enhance chemotherapy towards glioma
cells [46, 47]. Even then immunotherapy might still have to
be combined with other biological-based approaches such
as anti-angiogenesis to further improve immunotherapeutic
efﬁcacy [48].
Immunotherapy with or without autoimmunity?
Immunotherapy has had some clinical success against
some cancers when there are signs of autoimmunity
occurring. In melanoma, autoimmune responses against
non-tumorous melanocytes occur in a condition called
vitiligo. Cellular-based vaccines [49], interferon-alpha 2b
[50] -based therapies, and anti-CTLA-4 antibody therapies,
(which target self-T cell regulatory pathways), demonstrate
improved anti-cancer immune responses when simulta-
neously seeing some autoimmunity [51]. In bone marrow
transplantation (BMT) for hematological malignancies, a
similar debate occurred years ago. Here if some histo-
incompatibility between host and donor was included in the
BMT, a condition called graft-versus-leukemia occurred;
this was associated with better leukemia remissions [52,
53]. However, the ﬁne line cannot be crossed where life-
threatening graft-versus-host disease occurs. In most clin-
ical settings against brain cancers, little autoimmunity has
occurred as a result of whole cell vaccines. However,
temporary side effects do result in fever, skin rashes, and
myalgias, but these dissipate over the next few days,
without lasting effects. The results of these empirical
observations have lead to the debate whether one wants to
encourage autoimmune responses, as they may lead to
tumor cell destruction. In adult GBM use of mixed lym-
phocyte reactive (MLR) activated lymphocytes has the
potential to produce long-term survivals [37, 38]. One of
the concerns of this study was that autoimmunity could
occur, but empirical results have shown the concern was
unwarranted.
Immunotherapy of pediatric brain tumor patients
Although pediatric tumors express fewer known tumor
antigens compared with adult GBM, they do express about
nine tumor antigens (Art-1, EphA2, Fosl1, GnT-V,
HNRPL, Sox11, Ube2V, and YKL-40). These antigens
could be considered excellent possible immuno-targets.
Vaccination with dendritic cells pulsed with tumor lysates
or synthetic peptides that the patients’ tumors possess are
the best current approaches for immunotherapy.
The advantages to these patients are two-fold. First,
pediatric patients especially those around puberty should
possess the best immune responses in their lifetime. So
tumor antigen vaccination should boost an already strong
immune system. Studies show that young individuals make
stronger antibody titers and that less antigen is needed to
maximally stimulate their T cell responses [54, 55]. In
additional, the innate immune system is also diminished in
the elderly [56]. Immunotherapy of pediatric brain tumor
patients is already is considered safe with relatively few
side effects [57] and some increased survival have already
been reported [58].
Immunotherapy has several advantages for pediatric
patients. First, it could prevent the physiological and psy-
chological problems that radiation and chemotherapy
J Neurooncol (2010) 97:159–169 163
123cause, by perhaps reducing the amounts of radiation or
chemotherapy that are needed. Second, the predicted life
spans of these pediatric patients, especially with low grade
ﬁbrillary/protoplasmic astrocytomas and pilocytic astrocy-
tomas are given in years. Thus, there is ample time for the
immune system to work. Therefore, one could consider this
longer period of time, an ideal opportunity to do prophy-
lactic vaccination. Here the tumors are still relatively
small, slow growing but still susceptible to immune-med-
iated killing. This type of tumor burden also matches the
ability of various immunotherapies to control small, slower
growing tumors. Since pediatric GBM have fewer defense
mechanisms, these cancer cells should be controlled easier
by a fully activated and mobilized immune system.
Immune systems of young versus older people
Younger individuals have robust immune systems. Immu-
nity peaks around puberty, so these experimental successes
could be partly due to the vitality of the younger immune
systems. The majority of oncology patients, especially
GBM, are well past puberty, when their cancers appear. By
age 50, the human thymus has atrophied, so no new T cells
are produced. Those T cells that are still around may be
approaching replicative senescence, since they have already
divided many times and their teleromeres have signiﬁcantly
shortened. So these ‘‘exhausted’’ T cells coming from older
people don’t have the expansive vitality as those cells
coming from teenagers. In contrast, younger individuals’
thymus is still capable of generating T cell diversity, which
may speciﬁcally adapt to the brain tumor-associated anti-
gens. Similar conclusions have been recently been reviewed
by Jacobs and colleagues [59].
One direct application of this concept for adults with
GBM may include a strategy, where the immune cells from
a patient’s offspring are used for therapy in their parents.
Since the patient’s natural offspring share 1 HLA haplo-
type with themselves, the children’s DC and T cells could
be stimulated in vitro with the parent’s tumor. Better yet,
the grandchildren, if HLA matched could be used as a
source of the activated lymphocytes. These ex vivo stim-
ulated T cells could then be infused back into their parent
or grandparent with the glioma. These activated immuno-
cytes may then provide a more vigorous immune response
than the adult’s immunosenscent lymphocytes.
The concept of immunoprevention
Several years ago, Forni et al. [60], reviewed the problems
of human immunotherapy with end-stage cancer patients.
They suggested that the best use of immunotherapy might
be in controlling minimal residual disease, where there are
few cancer cells. They also proposed a concept called
immunoprevention. This is a very reasonable strategy for
those people who might be prone to develop cancer either
due to family genetics or due to the exposure of infectious
agents (HBV, HCV, HPV, H. pylori, etc.). Thus, this
immunopreventive strategy can stop a limited number of
cancers, i.e., hepatocellular carcinoma, cervical, stomach
cancer, etc. before they get ﬁrmly established. The other
critical issue here, is that the immune system is provided
ample time, so it can control these very small developing
cancers or pre-cancers. Many of these transformed cells
are also relatively slower growing tumors, when compared
to relapsing tumors. Most cancer patients don’t completely
respond well to immunotherapy because their tumors are
just too mutationally diverse, too big, and too fast grow-
ing. Also not sufﬁcient time is given to the immune sys-
tem to eliminate the tumor. If the immune system can
eliminate more cancer cells than the tumor cells can
replicate, then the cancer regresses. Thus, immunopre-
vention does have a strong appeal and should be used
whenever possible.
Immunotherapy may prevent the development
of secondary gliomas
One practical beneﬁt of immunotherapy for the treatment
of low grade gliomas is that it could prevent the risk of
developing secondary GBM. These secondary Stage IV
GBM evolve from prior low grade gliomas: pilocytic
astrocytomas (stage I), diffuse astrocytomas (stage II) or
anaplastic astrocytomas (stage III). Secondary gliomas
occur about 5–10% of the time. So if preventing secondary
GBM is desired, one could use all the antigens that GBM
possess (Table 1) and stimulate multiple T cell clones that
could prevent the progression to secondary GBM. How-
ever, the duration of the vaccination schedule and how long
it is effective against secondary GBM, all remain to be
elucidated. Recently, a report has described that metformin
(a drug used for diabetes management) can enhance CTL
memory cells [61]. So this drug may be very useful in
improving immunotherapy.
What tumor antigens should be targeted in pediatric
brain tumors?
What tumor antigens should be used to treat pediatric brain
tumor patients? Obviously, those antigens that the tumor is
making are the logical choice. Those vaccination programs
using autologous tumor are the best option for encom-
passing the entire tumor antigen spectrum.
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123But what happens if those autologous tumor antigenic
proteins are not sufﬁciently high in protein concentration to
induce immune responses, or not enough of the resected
tumor specimen is available for dendritic cell loading?
Synthetic peptides can be used to pulse the dendritic cells
prior to their induced maturation. But this requires that the
patient be HLA typed before therapy to insure that the
proper MHC binding sites are available. Most glioma
tumor antigens currently known are restricted for either
HLA-A2 or HLA-A24 (this just probably reﬂects a bias in
that most researchers just used HLA-A2 or HLA-A24
positive cancer cells). Using the entire TAPP fed to the
dendritic cells could also accomplish this same goal. This
strategy allows the DC to process all the peptides, so that
multiple antigenic determinants can be expressed on the
different MHC class I or class II alleles that each DC
expresses, allowing multiple T cell clones to get activated.
Best of all, perhaps other immunogenic peptides are being
generated that could enhance these anti-tumor immune
responses, via a process called epitope spreading [62]. Here
an immune response towards one immunodominant epitope
could stimulate other T cell clones that are recognizing
different determinants of the same antigen precursor
protein.
Many regulatory agencies and IRBs truly want to
advance the medical science by doing well-founded sys-
temic studies, where only a few antigens are tested to
assess vaccinating efﬁcacy; i.e. tetramer analysis, ELI-
SPOT, intracellular cytokine content, etc. This precludes a
shot-gun approach (via tumor homogenates), so that if
successes are found, it is nearly impossible to pinpoint
which antigens proved to be the key one(s). The danger
here with these very reﬁned studies where only a few
antigens are investigated, is that selection could produce
antigen negative variant cells. A current example of GBM
selection is the epidermal growth factor receptor variant III
(EGFRvIII) positive cells. After vaccination with dendritic
cells loaded with the EGFRvIII peptide, the EGFRvIII?
cells were effectively removed, while selecting EGFRvIII
negative clones [63].
In our study of TAPP proﬁles, we saw that some pedi-
atric patient’s GBM cells expressed low amounts of these
apoptosis-resistance genes, MRP-3, hTert and survivin.
Fortunately, tumor cells expressing these 3 antigens were
shown not to be resistant to T cell-mediated killing. We
believe it makes sense to include these tumor antigens in
immunotherapy trials, regardless of whether the patients’
current tumor possess these antigens. This proposed ther-
apy eliminates those cancer clones before they are fully
selected and before they can accumulate more defensive
proteins. Activated anti-MRP-3 and anti-hTert speciﬁc T
cells should eliminate these MRP-3 and hTert positive
cancer cells, thereby preventing the remaining cells from
being positively selected. This strategy might allow the
tumor to be more sensitive to classical chemotherapeutics,
thereby potentially reducing drug dosage and minimizing
the eventual side-effects. The proof of principal of this
concept occurred using the TRAMP mouse prostate cancer
model. Here prophylactic vaccination against mTert
delayed the tumor incidence in animal’s pre-disposed
prostate cancers [64].
Other tumor antigens that could be possible targets of
immunotherapy are CD133 and ATP-Binding Cassette,
subfamily G member-2 (ABCG2). Both of these markers of
‘‘stem cell’’-like genes. Both molecules function as reverse
chemotherapeutic drug transporters [65]. CD133? cells are
both radioresistant [66] and chemo-resistant [67], sug-
gesting these cells play a major role in being impervious to
various standard therapies. A high content of CD133?
cells within GBM has been reported to be associated with a
worse prognosis [68]. Maternal embryonic leucine zipper
kinase (MELK) is another tumor antigen that encodes for a
kinase, which is found in ‘‘glioma stem-like’’ cells [69];
MELK can stimulate CTLs [70]. Thus, ‘‘cancer stem cells’’
offer multiple targets for immunotherapy. By killing these
relatively scarce ‘‘stem cells’’ it should be easier to elim-
inate these tumor forming cells.
In conclusion, the best antigens to use for pediatric brain
tumors are those antigens that the current tumor is
expressing. Vaccination with these potential antigens,
MRP-3, hTert and survivin, may also prevent tumor escape
variants from being selected while ‘‘buying’’ the patient
more time. Immunization targeting stem cell antigens
should be included in the vaccine cocktail, since this could
eliminate the more potent cancer initiating cells. Thus, a
global vaccination strategy should cut potential tumor
growth on multiple different levels.
The feasibility of clinical trials
To conduct successful immunotherapy in children it will be
important to choose the right patient populations to show
clinical efﬁcacy, before immunotherapy will make it to
‘‘mainstream medicine’’. Figure 3 summarizes the 10 year
survival of four pediatric brain tumor patient populations,
pilocytic astrocytomas, ﬁbrillary/protoplastic astrocytomas,
ependymomas and GBM. These populations show a wide
spectrum of survival rates that can be theoretically
explored. Each population has its own positives and neg-
atives that need to be considered, before embarking on
immunotherapy.
Pediatric GBM as with adult GBM have a very poor
prognosis. Most of the mortality occurs within the ﬁrst
2 years, but then it levels off to a 20% survival for the next
8 years. If therapeutic vaccination has any effect in this
J Neurooncol (2010) 97:159–169 165
123population, it would be observed within the ﬁrst 2 years.
The limitation of using this patient population is similar to
that with adult GBM, in that tumor growth may be too fast
to be controlled by the immune system, unless the immune
response is incredibly potent.
Pediatric ependymomas have a better survival than
pediatric GBM. After 10 years survival is 50%. The death
rate is slower than GBM. One limiting factor with these
children is that the greatest incidence of ependymomas
occurs within children from birth to 4 years. Even though
children’s immune systems are developing, really young
children probably don’t have sufﬁcient immunity or sta-
mina that can be fully mobilized against a cancer. Func-
tional DC can be generated from pediatric cancer patients
of 1 year of age [71], but the yield of these DC from 3 to
4 year old patients can sometimes only yield 1–10 million
DC/vaccination [72]. These numbers of DC might be sub-
optimal for the desired therapeutic responses. So if therapy
is attempted with pediatric ependymomas, it should be
done in bigger children who should be able to generate the
necessary multiple millions of DC needed for reinfusion.
Fibrillary astrocytomas and pilocytic astrocytomas
patients have good survival rates: [80% for ﬁbrillary and
[90% for pilocytic astrocytomas. Thus, there is plenty of
time for the immunized lymphocytes to search out and
destroy these tumor cells. Fibrillary/protoplasmic astrocy-
tomas are unfortunately rare; only 142 are reported over the
last SEER report. To prove a statistical beneﬁt would
require a long time to accrue sufﬁcient numbers of patients.
So these tumors are probably not the ideal population to
study. Pilocytic astrocytomas are more common, with close
to a thousand described over the same time span. But the
major problem here is that their survival is greater than
90% for 10 years. So these proposed studies would require
many more patients be enrolled and extended survival
times would need to be examined to show some statistical
advantage. So these proposed studies would require very
long follow-up studies and very dedicated clinical
researchers.
Conclusions
Patients diagnosed with brain cancers have a very unfa-
vorable prognosis. A few patients do survive after various
therapies, so there is hope that brain tumors can be cured.
Pediatric patients survive much longer than adults afﬂicted
with the same pathologies. Immunity generally peaks at
puberty, so this may help explain why pediatric brain
tumor patients might survive longer. Young people have
more robust immune systems that might naturally enhance
their therapeutic interventions. We showed that pediatric
brain tumors express fewer tumor antigens when compared
to the adult GBM. Even though the total number of tumor
antigens is lower, those antigens could be the ones that
their immune systems are responding to and could be
attractive candidates for future immunotherapy. GBM
derived from adults appear very antigenic. But adult GBM
possess more defensive type molecules which make them
resistant to various therapeutic interventions. Since pedi-
atric tumors display lower levels of these ‘‘defense’’ type
antigens, these tumor-associated antigens make attractive
targets for immunopreventive interventions to prevent
more malignant clones from developing. We believe that
immunotherapy/immunoprevention may have its best suc-
cess as an adjunct therapy against pediatric brain tumors,
and could perhaps lower the dose and duration of radiation
or chemotherapy required to cure these younger patients.
This concept is actually modeled in most experimental
animal systems which use young mice and rats. However,
one thing is certain, these studies will be relatively chal-
lenging to conduct, since extended times are going to
needed to show whether signiﬁcant changes in survival has
occurred in response to vaccination.
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